Medicine company evaluates safety, engraftment and efficacy of VC-01 in patients with T1 Diabetes Mellitus
ViaCyte is starting a new clinical trial to Evaluate Safety, Engraftment, and Efficacy of VC-01 in Subjects With T1 Diabetes Mellitus.
VC01-103 will evaluate an experimental combination product, cell replacement therapy intended to provide a functional cure to subjects with Type 1 Diabetes.
The clinical trial started in June 25, 2019 and will continue throughout April 2023.
he percentage of graft cells present at post-implant time points relative to pre-clinical models is the primary outcome measure.
The population that can be enrolled into this study includes:
- Men and non-pregnant women
- Diagnosis of T1DM for a minimum of 3 years
- Stable, optimized diabetic regimen
- Acceptable candidate for implant and explant procedures
The contacts and locations are the Advanced Metabolic Care & Research Institute, Escondido, California;Diablo Clinical Research, Walnut Creek, California; Atlanta Diabetes Associates, Atlanta, Georgia and Texas Diabetes & Endocrinology, Austin, Texas, United States.
For more details: https://ichgcp.net/clinical-trials-registry/NCT04678557
